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A B S T R A C T
Background: A high risk of tuberculosis (TB), chronic lung disease, and mortality have been reported
among people with a history of previous TB treatment, but data from high-incidence settings remain
limited. The aim of this study was to characterize general morbidity and mortality among adults who had
successfully completed TB treatment in the past 5 years in a high-incidence setting in South Africa.
Methods: Adults (18 years) who had completed treatment for pulmonary TB between 2013 and 2017
were randomly selected from TB treatment registers. Household visits were conducted to locate and
interview former TB (FTB) patients, and bacteriological testing for TB was offered. Additional data sources
were used to ascertain the vitality status of FTB patients who could not be located.
Results: Addresses were located for 200 of the 223 FTB patients sampled and 89 FTB patients were
contacted of whom 51 agreed to be interviewed. Approximately half reported persistent respiratory
symptoms, such as shortness of breath and wheezing, and repeated lung infections. One (3.6%) of 28
patients who provided a sputum sample had culture-positive TB and another two were currently on
re-treatment for TB. Fifteen deaths post treatment were ascertained, resulting in a standardized
mortality ratio of 3.8 (95% confidence interval 2.3–6.3) after successful TB treatment relative to the
general population.
Conclusions: In this high-incidence setting, locating and interviewing FTB patients was challenging. The
study findings are consistent with a high rate of respiratory disease, including recurrent TB, and
substantially elevated mortality among FTB patients.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB), an airborne infectious disease caused by
Mycobacterium tuberculosis, accounts for considerable morbidity
and mortality worldwide, with an estimated 10 million TB cases
and 1.6 million TB deaths in 2017 (World Health Organization,
2018).
There is increasing awareness of the severe and potentially life-
threatening adverse health consequences of TB after completion of
treatment (Harries et al., 2016). Former TB (FTB) patients
frequently suffer from pulmonary sequelae, chronic obstructive* Corresponding author at: Desmond Tutu TB Centre, Department of Paediatrics
and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University,
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2021. For personal use only. No other uses without permisspulmonary disease (COPD) with impaired lung function, bronchi-
ectasis (Allwood et al., 2018; Hnizdo et al., 2000; Menezes et al.,
2007), pulmonary hypertension (Allwood et al., 2018), and residual
cavitation with secondary bacterial and fungal infections (Allwood
et al., 2018; Hedayati et al., 2015). In addition to non-TB lung
disease, there is also a high risk of recurrent TB after successful
treatment, associated with the extent of pulmonary involvement
during the initial TB episode and residual cavitation (Panjabi et al.,
2007; Rosser et al., 2018), and a higher risk of death compared to
the general population (Fox et al., 2019; Miller et al., 2015;
Shuldiner et al., 2016). Apart from health-related consequences,
FTB patients and their families are faced with severe socio-
economic challenges. Loss of income (Barter et al., 2012a),
catastrophic costs during TB treatment (Tanimura et al., 2014),
and lifelong disability with further loss of income may act as a
poverty trap (Mudzengi et al., 2017; Barter et al., 2012b Barter et al.,
2012b).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
ersity from ClinicalKey.com by Elsevier on October 21, 
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consequences post TB treatment has come from countries with
a relatively low burden of TB (van Kampen et al., 2018a);
there are limited data from high TB incidence settings.
Population-based studies in Uganda (van Kampen et al.,
2018b) and South Africa (Hnizdo et al., 2000; Amaral et al.,
2015; Buist et al., 2007; den Boon et al., 2007) have revealed a
high burden of respiratory symptoms, chest X-ray abnormali-
ties, and moderate to severe COPD, associated with a history of
previous TB treatment. FTB patients constitute a large group (10/
1000 population) in the adult population in several high TB
burden communities in South Africa and also account for a
considerable fraction of prevalent TB (19%) (den Boon et al.,
2007; Marx et al., 2016a Marx et al., 2016a), suggesting
opportunities for targeted TB control measures in this popula-
tion (Marx et al., 2018).
A random sample of adult FTB patients from a community
with a high TB incidence, who had successfully completed their
TB treatment in the preceding 5 years, were selected for this
pilot study. The aim was to determine whether it is feasible to
locate, contact, and survey FTB patients on the basis of routine
TB treatment records. A description of general and lung health
based on self-reported symptoms and sputum testing for TB is
given for the patients who were successfully contacted.
Ascertainment of vitality status from the field visits, as well
as from additional routine electronic data sources, was used to




This study was conducted in a community in suburban Cape
Town, South Africa, with a population of 60 528 in 2011 (StatsSA,
2018). Local TB services, including diagnosis, standard treatment,
and recording and reporting of TB cases, are provided by two local
primary health care clinics, in line with South African National TB
Programme (SA NTP) guidelines (National Department of Health,
2014). In 2017, 674 TB cases (57% co-infected with HIV) were
reported in this community — a TB case notification rate of 1033
per 100 000 population.
Study design
For this cross-sectional study, electronic TB treatment register
(ETR.Net) data were extracted for TB cases treated in the
community between January 1, 2013 and June 30, 2017. A random
sample of 256 adults (age 18 years) with bacteriologically
confirmed pulmonary TB was obtained, whose documented
standard TB treatment outcome was either ‘cure’ or ‘treatment
complete’. ‘Cure’ was defined as patients who had bacteriologi-
cally confirmed pulmonary TB at the beginning of TB treatment
and were then smear- or culture-negative in the last month of
treatment and at least one previous occasion during treatment.
‘Treatment complete’ included patients who had completed their
treatment without evidence of bacteriological failure, but with no
record of negative smears or cultures as defined in ‘cure’ (World
Health Organization, 2014). Randomization was stratified by year
of treatment registration.
Survey and data collection
Based on personal identifiers and recorded addresses, home
visits were conducted between March and May 2018, to locate and
contact FTB patients. Up to two separate home visits wereDownloaded for Anonymous User (n/a) at Stellenbosch Uni
2021. For personal use only. No other uses without permisconducted per address to locate and contact FTB patients.
Experienced field staff fluent in the local language (isiXhosa)
spoke to household residents and/or neighbours to locate FTB
patients. Participants who were successfully contacted and who
provided informed consent were interviewed using a standard
questionnaire, which included demographic and socio-economic
data, medical history of TB and other diseases, current TB and
pulmonary symptoms, and common TB risk factors. Participants
were further requested to provide a single sputum specimen.
Samples were transported to the National Health Laboratory
Services and tested using the Xpert MTB/RIF test (Xpert; Cepheid,
Sunnyvale, USA) and by culture (BACTEC MGIT; Becton Dickinson,
USA).
Use of additional data sources
Two further data sources were used to obtain additional
information about deaths (including date of death) among the
sampled FTB patients. Data from the patient-level Health
Information Exchange (HIE) of the Western Cape Government
Health Department were accessed. The HIE uses a unique health
system patient identifier and compiles individual routine
health-related data across all public health facilities in the
province (Heekes et al., 2018). The HIE was also searched for the
FTB patients’ South African identity numbers, which are not
recorded in the TB register. Where obtained, this was used to
ascertain the vitality status in the South African population
register.
Data analysis and mortality estimation
SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA)
was used for the data analysis. The analysis included descriptive
statistics of survey data and laboratory information obtained.
The rate of general mortality among FTB patients was
estimated as the number of TB deaths per 100 person-years
following the successful completion of TB treatment. Person-
time was calculated for FTB patients who were located during
the field work as the time between the documented TB
treatment outcome and the interview date, or a single date of
the field work for those FTB patients not interviewed. For
deceased individuals, the date of death, as recorded in the
electronic data sources, was used to ascertain the time since the
recorded TB treatment outcome.
The standardized mortality ratio (SMR) was estimated as the
ratio of deaths observed after TB treatment and the number of
deaths expected in the general population of the same age. For
standardization, we relied on age-specific estimates of general
mortality projected by the Thembisa model, a deterministic,
compartmental, mathematical model of the HIV epidemic in
South Africa (Johnson et al., 2016). The model uses age-specific
mortality probabilities for 1997–2010 derived from the South
African National Burden of Disease study and projects rates from
2011 onwards. At calibration of deaths in those between 20 and
59 years of age, the Thembisa model reported good agreement
between the modelled and recorded deaths (Johnson and
Dorrington, 2018). For each FTB patient identified in the study,
single-year mortality probabilities reflecting years of TB
registration, age, and sex were extracted from the Thembisa
model. The mortality probability and the person-time (years)
between the completion of TB treatment and the study were
used to estimate the expected deaths in the general population
per FTB patient profile. Two SMR estimates were calculated. The
first was based on deaths ascertained exclusively through the
survey; the second included deaths ascertained through
additional data sources.versity from ClinicalKey.com by Elsevier on October 21, 
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Description of the underlying population and sample
Between 2013 and 2017, a total of 2470 adult patients with
pulmonary TB (18 years) were treated in the study community. Of
these, 1734 (70%) had successfully completed their TB treatment
and 142 (5.7%) had died during TB treatment; 18.4% of patients
were lost to follow-up and 5% were transferred out. The mortality
rate during TB treatment was 15 deaths per 100 person-years. A
random sample of 256 individuals who had successfully completed
TB treatment was obtained; these patients did not differ from
those of the underlying cohort when stratified by year of
treatment, or clinical and demographic characteristics (Table 1).
Outcome of household visits
Tracings were completed by the study team for a total of 223 of
the 256 FTB patients initially sampled. Addresses were located for
200 of these 223 patients (90%) (Figure 1). Eighty-nine (45%) FTB
patients were successfully located, of whom 51 (57%) agreed to
participate in the survey. Other FTB patients had moved (n = 48;
24%) or could not be located (n = 52; 26%). The median time
between successful completion of TB treatment and interviewing
the FTB patient in this study was 2.6 years (interquartile range
(IQR) 0.8–3.4 years). The FTB patients interviewed did not differ
significantly from the patients who were not interviewed in terms
of baseline demographic and TB characteristics.
Survey results
Of the 51 surveyed participants, 32 (63%) were male, the
median age was 40 years (IQR 31–49 years), and 32 (63%) reported
some form of employment in the last 12 months. Eighteen (35%)
reported having had between two and four prior episodes of TB
treatment. About half (n = 26; 49%) were recorded as HIV-infected
at their last TB treatment. When asked, 36 of 51 were willing to
disclose their HIV status, with 19/36 (52%) reporting that they were
living with HIV. Fourteen (27%) of the 51 FTB patients reported a
current cough and 12 reported coughing for 2 weeks or longerTable 1
Comparison of TB treatment register characteristics between former TB patients samp
Variable Category 
Total 










TB patient category New case 
Retreatment 
Smear status Unknown 
Smear-positive 
Smear-negative 
HIV status Unknown 
Negative 
Positive 
TB treatment outcome Cured 
Treatment completed 
TB, tuberculosis.
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shortness of breath while walking up a hill or when walking fast
(28/51, 55%), needing to walk slower due to breathlessness (26/51,
51%), and wheezing (24/51, 47%). In addition, 15/51 (29%) reported
at least one severe chest infection in the preceding year (Table 2).
The profile of FTB patients is shown in Table 2: 32/51 (63%) FTB
patients had a smoking history, 41/51 (80%) reported previous or
ongoing use of alcohol, and 2/51 (4%) had been imprisoned in the
last 5 years. Thirty-five (69%) of the FTB patients were reliant on
some form of social support grant in the home, the most common
being a disability or child support grant.
Evidence of recurrent TB
Sputum was obtained from 28 FTB patients and one specimen
was Xpert and culture positive. The one positive specimen was
from a FTB patient who was known to local health services and at
the end of the second month of TB treatment. Subsequent follow-
up with routine health services indicated a good clinical response
and negative specimens thereafter. Two other FTB patients, who
were Xpert and culture negative, were currently on TB treatment at
the local TB clinic.
General mortality in the study sample
The field strategy was completed in 223 of the 256 sampled FTB
patients, and 11 (4.9%) deceased FTB patients were recorded. A
mortality rate of 2.1 deaths (95% confidence interval (CI) 1.2–3.8)
per 100 person-years was estimated, and an SMR of 3.1
(95% CI 1.7–5.5) (Table 3). The electronic databases were searched
for mortality information for the 156 FTB patients for whom
vitality status could not be confirmed via the survey (Figure 2). An
additional four deaths were documented in the HIE, for a total of 15
(5.9%) deaths among the 256 FTB patients. This resulted in an
overall mortality rate of 2.5 deaths (95% CI 1.5–4.1) per 100 person-
years, and an SMR of 3.8 (95% CI 2.3–6.3) (Table 3).
Figure 3 demonstratesthe overlap of the reporting sourcesfor the
15 confirmed deaths. Two thirds of the deceased FTP patients were
between 18 and 44 years of age; 9/15 (60%) were male and 12/15
(80%) were HIV-infected. All HIV-infected deceased patients wereled and not sampled for the study.
Sampled Not sampled
n Column % n Column %
256 100 1478 100
49 19.1 422 28.6
60 23.4 386 26.1
57 22.3 338 22.9
43 16.8 245 16.6
47 18.4 87 5.9
209 81.6 1165 78.8
41 16.0 277 18.7
6 2.3 36 2.4
91 35.6 572 38.7
165 64.4 906 61.3
172 67.2 974 65.9
84 32.8 504 34.1
46 18.0 285 19.3
107 41.8 603 40.8
103 40.2 590 39.9
0 0 11 0.7
103 40.2 591 40.0
153 59.8 876 59.3
101 39.5 563 38.1
155 60.6 915 61.9
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Figure 1. Overview of sampled former TB patients and the outcome of tracing activities. TB, tuberculosis; FTB, former TB.
aTwo hundred and fifty-six FTB patients were sampled, but due to time and logistical constraints, the pre-specified household tracing strategy could only be completed for 223
individuals.
bAn ongoing subsequent study in the same community has provided additional feedback: four of the 51 FTB participants interviewed in the present study were reported dead.
cOf the 38 who did not participate, one was too ill to participate, one denied having previous TB, and 14 cited time constraints due to work.
Table 2










Demographics Age category at the time of interview (years) 18–44 15 60 18 69 33 65
45–64 9 36 8 31 17 33
>64 1 4 0 0 1 2
Sex Female 6 24 13 50 19 37
Male 19 76 13 50 32 63
Self-reported chest illness and respiratory
symptoms
Current cough No 17 68 20 77 37 73
Yes 8 32 6 23 14 27
Duration of current cough
(n = 14)
<2 weeks 2 25 2 33 4 29
2 weeks 6 75 4 66 10 71
Severe chest illness in the last 12 months No 18 72 18 69 36 71
Yes 7 28 8 31 15 29
Shortness of breath while walking up hill or
fast
No 11 44 12 46 23 45
Yes 14 56 14 54 28 55
Needing to walk slower due to breathlessness No 12 48 13 50 25 49
Yes 13 52 13 50 26 51
Wheeze No 14 56 13 50 27 53
Yes 11 44 13 50 24 47
Socio-economic profile Ever smoked No 8 32 11 42 19 37
Yes 17 68 15 58 32 63
Alcohol use Have never drunk 6 24 4 15 10 20
Daily drinker 0 0 1 4 1 2
Occasional drinker 13 52 18 69 31 61
Ex-drinker 6 24 3 12 9 18
Imprisoned in the last 5 years No 25 100 24 92 49 96
Yes 0 0 2 8 2 4
Type of social support grant in home if
applicable
(n = 35)
Disability grant 7 44 8 42 15 43
Child support grant 7 44 12 63 15 43
Grants for older
persons
3 19 2 11 3 9
Foster care grant 2 13 1 5 2 6
Care dependency
grant
0 0 2 11 2 6
TB, tuberculosis.
60 M. Osman et al. / International Journal of Infectious Diseases 85 (2019) 57–63recorded as having been on antiretroviral therapy (ART) and
co-trimoxazole prophylaxis during the TB episode. Thirteen patients
had a confirmed date of death; the median time to death was 1.43
(IQR 0.48–2.16) years after successful completion of TB treatment.
The date of death was unknown for two deceased FTB patients, and
the average person-time of the 13 other deceased FTB patients was
used to estimate the time between TB treatment and death.Downloaded for Anonymous User (n/a) at Stellenbosch Uni
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This study showed that tracing and locating FTB
patients was time-consuming and difficult, despite available
records of addresses in the electronic TB treatment register.
Although it was possible to locate households from the
addresses stored in the register, a large proportion of FTBversity from ClinicalKey.com by Elsevier on October 21, 
sion. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 3
Mortality rates and standardized mortality ratios for former TB patients using the vitality status as determined by two different search strategies.












Field work 223 11 525.5 2.1 (1.2–3.8) 3.6 3.1 (1.7–5.5)
Using additional
electronics searches
256 15 608.8 2.5 (1.5–4.1) 4.0 3.8 (2.3–6.3)
TB, tuberculosis; CI, confidence interval. The mortality rate is expressed as the number of deaths per 100 person-years of follow-up. The standardized mortality ratio is
calculated as the number of observed deaths/expected deaths.
a An ongoing subsequent study in the same community has provided additional feedback: four of the 51 former TB participants interviewed were reported dead; these
deaths, which occurred after the present study, are not included in the estimates.
b ‘Expected deaths’ reflects the number of deaths that should have occurred based on the mortality probability in the Thembisa model for the Western Cape.
Figure 2. Overview of the search of additional electronic sources for vitality status
of former TB patients not definitively ascertained in the field work (n = 156). HIE,
health information exchange; TB, tuberculosis; SA, South Africa; ID, national
identity number.
aHIE searched for South African identity numbers.
bHIE searched for mortality.
*Two of the three deceased were documented in the SA population register as
deceased.
**The SA population register could not be searched as it is dependent on the use of
an SA ID number.
Recorded as dead is as applied in the electronic register. Not dead does not
automatically imply alive status but rather not recorded as dead.
M. Osman et al. / International Journal of Infectious Diseases 85 (2019) 57–63 61patients had moved away or they were otherwise unable to
participate.
Breathlessness and lung function loss after TB treatment are
well documented (Ross et al., 2010; Allwood et al., 2013; van
Kampen et al., 2019), and patients with chronic lung disease who
have previously had TB have been shown to have chronic
respiratory symptoms and recurrent hospital admissions (Mkoko
et al., 2019). In the BOLD study, TB and smoking were associated
with increased shortness of breath (Grønseth et al., 2014), and an
earlier work showed that a chronic productive cough among South
African adults was associated with previous TB, smoking
occupational exposures, and domestic fuel exposure (Ehrlich
et al., 2004). A systematic review has confirmed the increased risk
of TB among smokers (Lin et al., 2007). In the present study, it was
noted that 63% of interviewed FTB patients had a smoking history,
and while lung function was not objectively measured and no
attempt was made to classify chronic lung disease, it was possible
to confirm that FTB patients who were successfully located
commonly reported respiratory symptoms such as shortness of
breath and wheezing, as well as repeated lung infections,
consistent with chronic pulmonary impairment.Downloaded for Anonymous User (n/a) at Stellenbosch Univers
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TB; all had been detected by routine health services and initiated
re-treatment. This finding of recurrent TB is consistent with
earlier studies reporting a high prevalence of TB among FTB
patients, who may also account for a high proportion of prevalent
TB overall in communities (den Boon et al., 2007; Marx et al.,
2016b Marx et al., 2016b). A recent modelling study suggested
that active case finding and secondary prevention among FTB
patients could substantially decrease TB morbidity and mortality
in high-incidence settings (Marx et al., 2018), but trials of such
targeted approaches have not been conducted.
This study reports a mortality rate after TB treatment exceeding
that of the general population by several-fold, despite the
successful course of TB treatment. The findings are consistent
with those of an earlier study in a low burden setting, which
followed FTB patients for a median of 5.9 years and documented an
SMR of 3.7 (Shuldiner et al., 2016). More recently, an SMR of 4.0
(95% CI 3.7–4.2) for mortality after the start of TB treatment was
reported in Vietnam, but this included mortality both during and
after TB treatment (Fox et al., 2019). In that study from Vietnam,
two thirds of deaths occurred after patients had been discharged
from TB treatment (Fox et al., 2019). In a study conducted in
Zimbabwe, Chin et al. noted that successfully treated TB patients
had a 6-fold increased rate of mortality compared to the HIV-
infected population and 15-fold increased rate of mortality
compared to the general population in the first year after TB
treatment (Chin et al., 2019). In the present study, a high
proportion of those who were confirmed dead were HIV-infected,
and although documented as on ART during treatment, this
included those on ART prior to TB treatment and those starting ART
during the TB treatment episode. The role of HIV, compliance with
ART, and the degree of viral load suppression in the final cause of
death could not be ascertained.
This was a pilot study of limited size and has important
limitations. While it was possible to locate 90% of addresses of FTB
patients, it was only possible to contact and interview less than half
of the FTB patients. The ability to definitively locate FTB patients
may vary depending on migrant patterns of specific communities
and should be investigated further. Of the FTB patients located, a
large number declined participation due to competing commit-
ments. Interviewed patients did not differ from those who declined
participation in terms of baseline characteristics. However, it is not
possible to exclude the possibility that those who declined
participation represented healthier individuals. While more
objective measures of lung function or radiographic examinations
were not performed, this study provided the basis for a more
comprehensive study in the same location to quantify the loss of
lung function. Following the field survey component of the study,
additional data sources were used to obtain information on
mortality. It was noted that neither strategy was complete and that
deaths were missed in field work and electronic data searches. The
reported mortality rates are documented for each strategy and
likely represent underestimates, as it was assumed that FTBity from ClinicalKey.com by Elsevier on October 21, 
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Figure 3. Venn diagram documenting the overlapping mortality sources in the
confirmation of death and the number of deaths recorded through each source for
the 15 documented deaths among former TB patients.
62 M. Osman et al. / International Journal of Infectious Diseases 85 (2019) 57–63patients were alive when vitality status could not be ascertained.
This has likely resulted in conservative estimates of mortality after
TB treatment. It was not possible to determine the definitive cause
of death or disentangle the effect of HIV and ART on mortality and it
is acknowledged that we report all-cause mortality after TB
treatment.
In conclusion, this study highlights a substantial burden of
prevalent TB, symptoms of chronic lung impairment, and general
mortality among FTB patients. Additional research and public
health efforts are also needed to ensure proper management of
adverse health consequences post TB in order to minimize these
consequences, especially in high TB burden settings. The fact that
FTB patients are in contact with the health system for the duration
of TB treatment creates opportunities for secondary prevention,
including appropriate education, follow-up, and treatment for
individuals with lung impairment.
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